Name | 17-(3-pyridyl)-5,16-androstadien-3beta-acetate |
Synonyms | ZYTIGA CB 7630 Abirteroneacetate Abiraterone Acetate Abiraterone Acotate Abiraterone Acetate impurity 17-(3-pyridyl)-5,16-androstadien-3beta-acetate (3β)-17-(3-pyridinyl) androsta-5,16-dien-3-yl acetate (3)-17-(3-Pyridinyl)androsta-5,16-dien-3-ol Acetate (Ester) (3beta,8xi,9xi,14xi)-17-(pyridin-3-yl)androsta-5,16-dien-3-yl acetate [(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate (3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate |
CAS | 154229-18-2 |
EINECS | 620-314-7 |
InChI | InChI=1/C26H33NO2/c1-17(28)29-20-10-12-25(2)19(15-20)6-7-21-23-9-8-22(18-5-4-14-27-16-18)26(23,3)13-11-24(21)25/h4-6,8,14,16,20-21,23-24H,7,9-13,15H2,1-3H3/t20-,21?,23?,24?,25-,26+/m0/s1 |
Molecular Formula | C26H33NO2 |
Molar Mass | 391.55 |
Density | 1.14±0.1 g/cm3(Predicted) |
Melting Point | 127-130°C |
Boling Point | 506.7±50.0 °C(Predicted) |
Flash Point | 260.2°C |
Solubility | Chloroform (Slightly), DMSO (Sparingly), Methanol (Sparingly) |
Vapor Presure | 2.17E-10mmHg at 25°C |
Appearance | powder |
Color | white to beige |
pKa | 5.31±0.12(Predicted) |
Storage Condition | -20°C |
Refractive Index | 1.583 |
Physical and Chemical Properties | Abiraterone acetate is a CYP17 inhibitor suitable for use in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer who have received prior docetaxel-containing chemotherapy. |
In vitro study | Abiraterone showed good complexation with heme iron only in SM1. Abiraterone blocks androgen synthesis by inhibiting CYP17A1. Abiraterone also blocks 3β-hydroxysteroid dehydrogenase (3βHSD), an enzyme that is completely dependent on biologically active androgen synthesis. Abiraterone inhibits the conversion of DHEA to Δabiraterone inhibits C 17,20-lyase with an IC50 of 5.8 nM in rat testis microsomes. Abiraterone significantly inhibited testosterone secretion (− 48%) and in turn increased LH concentrations (192%). Abiraterone inhibits the in vitro proliferation of AR-positive prostate cancer cells and the expression of AR-regulated genes, which may be due to AR antagonism in addition to Steroidogenesis inhibition. |
In vivo study | abiraterone was administered to rats by intraperitoneal injection, and abiraterone was rapidly deacetylated in vivo. CB7630(Abiraterone Acetate) is a de-Acetate prodrug that suppresses circulating testosterone below detectable levels and significantly reduces the weight of androgen-sensitive organs. Abiraterone was well tolerated with a mean elimination half-life of 27.6 hours. Preclinical studies in mice have shown that abiraterone inhibits CYP17, reduces androgen production, and can lead to weight loss in the prostate, testes, and seminal vesicles. |
WGK Germany | 3 |
RTECS | BV7992100 |
HS Code | 2937290000 |